ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HLA-A*02:01/p53 R175H Bispecific T-cell Engager CLSP-1025

Its studies are mostly in Neoplasm Metastasis, led by Clasp Therapeutics.

Furthest: phase 1, since Jan 8, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Clasp Therapeutics11 open or runningphase 1since Jan 8, 2025Jan 8, 2025Dec 2027phase 1 · NCT06778863

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2025First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06778863 · 90 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT06778863

TargetBeta

CD3E →TP53 →read by rule
“An asymmetric bispecific single-chain diabody (scDb) Fc fusion protein and T-cell engager (TCE) directed against the human TP53 (p53) R175H mutant peptide (p53(R175H)168-176) bound to human leukocyte antigen (HLA)-A*02:01 (HLA-A*02:01) and the T-cell-specific antigen CD3epsilon (CD3e), ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06778863Neoplasm Metastasis · United States1RecruitingDec 202790

How it is read

Names in the registry

  • “CLSP-1025”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.